The Pathogenesis and Prognostic Factors of Lymphoma

NCT06203652 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Zhongshan Hospital

Phase

Observational

Started

2023-06-05

Last updated

2024-01-12

Condition(s) studied

LymphomaHodgkin LymphomaNon-hodgkin Lymphoma

Investigational drug(s) / intervention(s)

Real-world regimen

Real-world regimen: The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on

Study summary

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027. * Patients with complete diagnostic, treatment and follow-up records. * Fully comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. * Severe mental illness. * Patients deemed unsuitable for inclusion by the investigator.

Primary outcome measure(s)

OS — Baseline up to data cut-off (Up to approximately 20 years)
Overall survival (OS) refers to the time from receiving the first dose to death from any cause

Trial sites (1)

Facility	City	Region	Status
Zhongshan Hospital，Fudan University	Shanghai	Shanghai Municipality	Recruiting

More Shanghai Zhongshan Hospital trials in China

A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components Recruiting

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia Recruiting

ICCA-Based ICU Physiological State Space Monitor Active, not recruiting

Prospective Acute Myocardial Infarction Data Bank Starting soon

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma Recruiting

Other trials for the same condition

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma Starting soon

PIC1 Injection Therapy for Relapsed/Refractory B-NHL Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Active, not recruiting

Study of AXT-1003 in Subjects With Advanced Malignant Tumors. Recruiting

CD70-targeted immunoPET Imaging of Malignant Cancers Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06203652 on ClinicalTrials.gov ↗ ← All trials in China